Report workspace

Add to folder
NCT00104741COMPLETEDanonymous

Multicentre Randomized Trial Assessing the Efficacy of a Short Neoadjuvant and Concomitant Hormone Therapy to an Exclusive Curative Cornformational Radiotherapy of Locolized Prostate Cancer With Intermediate Prognosis

Sponsor

Source record

UNICANCER

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

flutamide, triptorelin, radiation therapy

Indication / condition

AI-normalized

Prostate Cancer

Intervention

Source record

flutamide, triptorelin, radiation therapy

Source & freshness

Source record

NCT ID

NCT00104741

Original source

ClinicalTrials.gov

Source last updated

Feb 21, 2021

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00104741

Title

Multicentre Randomized Trial Assessing the Efficacy of a Short Neoadjuvant and Concomitant Hormone Therapy to an Exclusive Curative Cornformational Radiotherapy of Locolized Prostate Cancer With Intermediate Prognosis

Sponsor

UNICANCER

Status

COMPLETED

Phase

PHASE3

Condition raw

Prostate Cancer

Condition normalized

Prostate Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

flutamide, triptorelin, radiation therapy

Target normalized

flutamide, triptorelin, radiation therapy

Interventions

flutamide, triptorelin, radiation therapy

Public preview

Source record

RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as triptorelin and flutamide, may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving triptorelin and flutamide together with radiation therapy may be an effective treatment for prostate cancer. It is not yet known whether giving triptorelin and flutamide together with external-beam radiation therapy is more effective than external-beam radiation therapy alone in treating prostate cancer.

PURPOSE: This randomized phase III trial is studying triptorelin, flutamide, and external-beam radiation therapy to see how well they work compared to external-beam radiation therapy alone in treating patients with stage II or stage III prostate cancer.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account

Create a free account first, then unlock a single report, buy credits or subscribe.